BCAX Bicara Therapeutics Inc. Common Stock
Healthcare$21.68+4.03%ClosedMarket Cap: $1.19B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.56
P/S
0.00
EV/EBITDA
-5.10
DCF Value
$1.64
FCF Yield
-9.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.9%
ROA
-28.4%
ROIC
-33.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-60.2M | $-56.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-41.1M | $-37.4M | $— | — |
| FY null | $0.00 | NaN% | $-155.6M | $-137.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-40.7M | $-36.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-32.0M | $-27.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-41.8M | $-36.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-26.6M | $-21.0M | $— | — |
| FY null | $0.00 | NaN% | $-82.4M | $-68.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-20.6M | $-17.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-19.8M | $-17.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.4M | $-12.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-13.7M | $-12.4M | $-0.23 | — |